Foresite Capital Management

Foresite Capital Management is a U.S. healthcare and life-sciences multi-stage venture capital and growth-equity firm headquartered in San Francisco (with an operating office in Larkspur), California, founded in 2011 by CEO and Founder Dr. Jim Tananbaum (Yale BS and BSEE Applied Math and EECS; Harvard MD and Harvard/MIT HST Program graduate; Harvard Business School MBA; co-founder of GelTex Pharmaceuticals [NASDAQ: GENZ, eventually acquired by Genzyme for USD 1.6 billion] and Theravance / Innoviva; CEO of Sirna Therapeutics). The firm focuses on the development and commercialization of transformative healthcare products addressing critical unmet medical needs across precision therapeutics, life-sciences infrastructure / tools, digital and data-driven healthcare delivery, genomics, and adjacent healthcare-and-technology themes, investing across all stages from seed through pre-IPO and post-IPO crossover / PIPE rounds. Foresite has raised six flagship funds since 2011 (Fund I USD 100 million 2013; Fund II USD 300 million 2014; Fund III USD 450 million 2015; Fund IV USD 668 million 2018; Fund V USD 776 million core + USD 194 million opportunities = USD 969 million in 2021; Fund VI USD 900 million in May 2024) plus Foresite Labs Fund I at USD 173 million (2022), with aggregate AUM of approximately USD 3.5-4+ billion. The firm has delivered 47 IPOs, 28 M&A exits, and 58 FDA-approved drugs across its portfolio history. Notable portfolio companies include 10x Genomics (NASDAQ: TXG), Amerigroup / Anthem (NASDAQ: ANTM), Jazz Pharmaceuticals (NASDAQ: JAZZ), Alumis, Hims & Hers Health (NYSE: HIMS), CG Oncology, Latigo Biotherapeutics, Element Biosciences, Insitro, Xaira Therapeutics (USD 1 billion incubation with ARCH Venture Partners, April 2024), Disc Medicine, Eikon Therapeutics, and NanoString Technologies.